TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
A Cell Reports study showcases how vivoPHIX™ enables simultaneous single-cell RNA and phospho-signalling analysis, uncovering dynamic Th17 states with implications for immunology, diagnostics, and beyond.
New protocol from NIAID researchers uses vivoPHIX™ to stabilise RNA at the point of collection — enabling clean, high-quality single-cell sequencing from insect tissues without enzymes, heat, or cold chain.
Dr Andrew Goldsborough will be presenting "TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines" at 15:45 on 12th June 2025
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com